Philadelphia ranks second in a newly released study comparing 14 U.S. cell and gene therapy hubs in five key categories.
The categories include research infrastructure, human capital, innovation output, commercial activity, and value proposition. The only region that ranked higher overall than Philadelphia was Boston. New York and San Francisco were ranked third and fourth, respectively.
The study was commissioned by the The Chamber of Commerce for Greater Philadelphia and researched by economic consulting firm Econsult Solutions, Inc. (ESI).
“The Philadelphia region is increasingly attracting new and expanding cell and gene therapy companies because it checks all the boxes, but it’s the region’s research infrastructure as defined by NIH-funded cell and gene therapy research and its large number of research institutions that give it the edge,” said Claire Marrazzo Greenwood, Executive Director, CEO Council for Growth and Senior Vice President of Economic Competitiveness for the Chamber. “Combining our research infrastructure with a track record of innovation output including the first FDA approved cell and gene therapies make Philadelphia an excellent place to locate or to expand a cell and gene therapy business.”